A rationally designed triple GLP-1R/GCGR/GIPR agonist peptide with intentionally weak GIPR activation matched retatrutide's metabolic effects and outperformed tirzepatide for weight loss in preclinical testing.
Weight loss > tirzepatideThe triple agonist xGLP/GCG/GIP-32 achieved superior weight reduction compared to tirzepatide despite having much weaker GIPR activation
What the researchers found
Researchers designed a novel triple-receptor agonist peptide (xGLP/GCG/GIP-32) that activates GLP-1R and GCGR potently but GIPR only weakly. Despite this intentionally unbalanced activation profile, the compound achieved weight loss effects superior to tirzepatide (a dual GLP-1R/GIPR agonist) and metabolic efficacy comparable to retatrutide (a triple agonist), both of which are leading obesity/diabetes drugs.
The study revealed that xGLP/GCG/GIP-32 exhibits biased agonism toward GIPR and GCGR, suggesting that maximal potency at all three receptors may not be necessary — and that strategically tuning the ratio of receptor activation could be a more effective design approach for next-generation metabolic peptide drugs.
Why it matters
The obesity drug pipeline is intensely focused on multi-receptor agonists following the success of semaglutide and tirzepatide. This study challenges the assumption that stronger activation at every target receptor leads to better outcomes, opening the door to more nuanced peptide drug design. If biased agonism at specific receptors proves advantageous, it could lead to drugs with better efficacy-to-side-effect profiles.
How the study worked
The researchers used sequence analysis, molecular dynamics simulations, molecular docking, and amino acid optimization to rationally design triple agonist peptides based on the GLP-1 scaffold. Lead compounds were tested for receptor activation profiles at GLP-1R, GCGR, and GIPR, then evaluated for metabolic effects including weight loss and glycemic control in animal models, with comparisons to tirzepatide and retatrutide.
Who was studied
Mouse models (preclinical drug design study)
What this study cannot tell us
This is a preclinical study — the compounds have only been tested in animal models (mice), not in human clinical trials. The comparison to tirzepatide and retatrutide was based on preclinical metrics, which may not predict relative efficacy in humans. Long-term safety and tolerability data are not available.
How to read the evidence
This is a preliminary-grade preclinical drug design study. While the rational design approach is rigorous and the comparisons to approved drugs are informative, all data come from mouse models. Human clinical trials are required to validate these findings.
When this study was published
Published in 2025, this is very recent research at the cutting edge of multi-receptor agonist peptide drug design.
The bigger picture
The incretin-based drug revolution — led by semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — is now pushing toward triple-receptor agonists like retatrutide. This study adds nuance by showing that receptor activation balance, not just potency, may determine effectiveness. It could reshape how the next wave of obesity and diabetes peptide drugs are engineered.
Questions still open
- Could biased agonism at GIPR reduce gastrointestinal side effects that are common with potent incretin drugs, while preserving metabolic benefits?
- What is the optimal GLP-1R:GCGR:GIPR activation ratio for maximizing weight loss with minimal adverse effects in humans?
- How would xGLP/GCG/GIP-32 perform in longer-term studies and in models of comorbid conditions like fatty liver disease?
Common questions
How does this triple agonist compare to existing drugs like Ozempic and Mounjaro?
What is biased agonism and why does it matter here?
Read the original research
Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects.
Journal of medicinal chemistry, 68(19), 20765-20788
Citation
Wang, Shuang; Liu, Yun; Yan, Zhiming; Huang, Xianxian; Liao, Yonghe; Tang, Chunli; Jing, Lin; Zhou, Zhongbo; Han, Jing; Tang, Weizhong; Jiang, Neng. (2025). Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects.. Journal of medicinal chemistry, 68(19), 20765-20788. https://doi.org/10.1021/acs.jmedchem.5c02032